Search bioRxiv⌕ Search

Biology subjects

Splinter, T.

Publications and source records attributed to Splinter, T..

3 recordsLinked to original sources

Reproductive history differentially shapes the neural response of middle-aged females to estradiol therapy after a metabolic challenge

BackgroundAdvancing age, the APOE{square}4 allele, and female sex are the top nonmodifiable risk factors for Alzheimers disease (AD). Female-specific experiences, such as parity and hormone therapy (HT) affect aging biomarkers such as metabolism and immune signaling and may even affect AD risk. Estradiol (E2), a common component of many HTs, affects cognition and brain health in aging females although this may vary depending on parity, genotype, and metabolic status. We hypothesized that prior parity influences brain and metabolic health, including response to E2, depending on APOE genotype. MethodsMiddle-aged female (10 month) wildtype (WT) or humanized (h) APOE{square}4 expressing rats, with different reproductive experience (nulliparous or primiparous) were fed a Western (WD) or standard diet (SD) for 2 months. In the second month, rats were given E2 or vehicle (oil) injections daily. Fear associative learning, plasma metabolic hormones, hippocampal inflammatory signalling, and neuroplasticity (neurogenesis, synaptic protein) were assessed. ResultsFemales fed a WD gained weight and displayed metabolic dysregulation, regardless of genotype. E2 treatment reduced WD-induced weight gain and reduced metabolic hormones, with stronger effects in WT rats. E2 treatment increased dorsal hippocampal inflammatory signalling selectively in primiparous hAPOE{square}4 females fed a WD. Previous parity increased neurogenesis and reduced certain cytokines in the hippocampus of middle-aged WT rats under a SD. Both E2 treatment and previous parity decreased dorsal neurogenesis in hippocampus of hAPOE{square}4 rats. In hAPOE{square}4 females, higher weight was associated with reduced contextual fear memory, an effect driven by primiparous females. In the cued fear conditioning task, hAPOE{square}4 females displayed better cued fear memory than WT, however, WD exposure reduced cued fear memory in this group. Together, this indicates that diet and weight gain may be more detrimental to associative memory in hAPOE{square}4 females and that E2 treatment has more favourable outcomes in WT rats. ConclusionsPrevious parity alters how females respond to E2 and metabolic stress in midlife. Primiparous hAPOE{square}4 females were especially vulnerable to the effects of WD and E2, exhibiting more inflammation, impaired memory, and reduced weight-loss. These findings highlight the importance of considering parity and genotype when evaluating midlife metabolic and cognitive risk. HighlightsO_LIEstradiol (E2) treatment reduced body weight gain under a Western diet (WD), with the most pronounced effects in wildtype primiparous rats. C_LIO_LIWD increased several metabolic hormones, and E2 treatment reduced several metabolic hormones after a WD in middle age, only in WT rats C_LIO_LIIncreased body weight impaired contextual associative memory in primiparous hAPOE{square}4 females. C_LIO_LIE2 treatment increased dorsal hippocampal inflammatory signalling in primiparous hAPOE{square}4 rats and the WD increased inflammatory signalling in primiparous WT rats. C_LIO_LIPrevious parity, but not E2 treatment, increased neurogenesis in WT rats only under standard diet conditions whereas a WD decreased neurogenesis based on genotype and previous parity C_LI Plain English SummaryAlzheimers disease (AD) causes general cognitive decline, and females are at higher risk than males, particularly those carrying the APOE{varepsilon}4 gene. Female-specific experiences, such as previous pregnancy (parity) and hormone therapy, as well as lifestyle factors like body weight and diet, may further influence AD risk. We examined how estradiol (E2), a hormone involved in the menstrual cycle, pregnancy, and some hormone therapies can affect memory, brain inflammation, synaptic plasticity (brain cell connectivity), and growth of new neurons (neurogenesis) in middle-aged female rats. We compared females with or without the APOE{varepsilon}4 gene and with or without prior parity, fed either a high-fat, high-sugar Western diet (WD) or a standard diet (SD). WD increased body weight and worsened metabolic health, but the strength of negative effects depended on genotype and pregnancy history. In females with the APOE{varepsilon}4 gene and prior parity, higher body weight was linked to poorer memory. hAPOE{varepsilon}4 females on SD showed better memory than non-carriers but this benefit disappeared on WD, suggesting WD and obesity are particularly detrimental for hAPOE{square}4 carriers with prior parity. WD-fed primiparous hAPOE{square}4 females treated with E2 also showed higher brain inflammation than other groups. Pregnancy history and E2 treatment were associated with more favourable outcomes in females without the genetic risk for AD and fed a standard diet. These findings highlight the importance of a personalized approach to hormone therapy and brain health in aging females. hAPOE{square}4 females with prior parity were most sensitive to the effects of diet. Together, this suggests genetic background, reproductive history, and diet interact to affect memory, inflammation, and neurogenesis, as well as the effects of E2 on these factors.

neuroscience↗

Conjugated GLP-1 and Estradiol Treatment as a Novel Treatment for Age-related Cognitive Decline in Males and Females

Middle age represents a critical window for metabolic and cognitive health, particularly in the context of rising obesity and diabetes rates. Glucagon-like peptide-1 (GLP-1)-based therapies, which regulate blood glucose and body weight, show sex-specific effects, with estradiol potentiating their metabolic benefits. However, research on GLP-1s cognitive and neuroprotective roles has largely been conducted in males. Here, we investigated the effects of GLP-1 conjugated to estradiol (GE2) on metabolism, cognition, cytokine levels and neurogenesis in the dentate gyrus of middle-aged male and female rats fed a standard (SD) or Western (WD) diet. In both sexes, WD increased body weight and plasma leptin levels, regardless of sex. GE2 treatment led to weight loss, enhanced cued and contextual fear memory, reduced cytokine levels in the hippocampus in SD rats, and increased neurogenesis in the dorsal dentate gyrus (DG), regardless of sex. Sex-specific differences were observed in fat distribution, glucose regulation, central cytokine levels, and neuroplasticity after WD and GE2 treatment. In females only, GE2 reduced visceral (gonadal) fat, reduced cytokines in the dorsal hippocampus, and improved basal blood glucose in response to a WD. In males only, GE2 restored neurogenesis in the DG after WD exposure, and reduced cytokine levels in the amygdala. These findings suggest that although WD increased body weight and GE2 improved associative learning in both sexes, both WD and GE2 had differential affects on metabolic hormones, insulin regulation, cytokine levels and neuroplasticity. Our findings underscore the importance of sex-specific approaches in metabolic and neuroprotective therapeutics in middle age.

neuroscience↗

Are we moving the dial? An evaluation of sex- and gender-based analysis integration in Canadian Institutes of Health Research-funded research from 2009-2020

BackgroundSex and gender impacts health outcomes and disease risk throughout life. The health of women and members of the Two-Spirit, Lesbian, Gay, Bisexual, Transgender, Queer or Questioning, Intersex, and Asexual (2S/LGBTQ+) community is often compromised as they experience delays in diagnosis. Distinct knowledge gaps in the health of these populations has prompted funding agencies to mandate incorporation of sex and gender into research. Sex-and gender-informed research perspectives and methodology increases rigor, promotes discovery, and expands the relevance of health research. Thus, the Canadian Institutes of Health Research (CIHR) implemented a Sex and Gender-based Analysis (SGBA) framework recommending the inclusion of SGBA in project proposals in 2010 and then mandating the incorporation of SGBA into grant proposals in 2019. To examine whether this mandate resulted in increased mention of sex or gender in funded research abstracts, we searched the publicly available database of grant abstracts funded by CIHR to analyze the percentage of abstracts that mentioned sex or gender of the population to be studied. To better understand broader health equity issues we also examined whether the funded grant abstracts mentioned either female-specific health research or research within the 2S/LGBTQ+ community. ResultsWe categorized a total of 8,964 Project and Operating grant abstracts awarded from 2009- 2020 based on their study of female-specific or a 2S/LGBTQ+ populations or their mention of sex or gender. Overall, under 3% of grant abstracts funded by CIHR explicitly mentioned sex and/or gender, as 1.94% of grant abstracts mentioned sex, and 0.66% mentioned gender. As one of the goals of SGBA is to inform on health equity and understudied populations with respect to SGBA, we also found that 5.92% of grant abstracts mentioned female-specific outcomes, and 0.35% of grant abstracts focused on the 2S/LGBTQ+ community. ConclusionsAlthough there was an increased number of funded grants with abstracts that mentioned sex and 2S/LGBTQ+ health across time, these increases were less than 2% between 2009 to 2020. The percentage of funded grants with abstracts mentioning female-specific health or gender differences did not change significantly over time. The percentage of funding dollars allocated to grants in which the abstracts mentioned sex or gender also did not change substantially from 2009-2020, with grant abstracts mentioning sex or female-specific research increasing by 1.26% and 3.47% respectively, funding allocated to research mentioning gender decreasing by 0.49% and no change for 2S/LGBTQ+-specific health. Our findings suggest more work needs to be done to ensure the public can evaluate what populations will be examined with the funded research with respect to sex and gender to advance awareness and health equity in research. HighlightsO_LIThe percentage of funded grants in which the abstracts mentioned sex or gender in health research remained largely unchanged from 2009 to 2020 with the largest increase of 1.57% for those mentioning sex. C_LIO_LITotal funding amounts for grants that mentioned sex or gender in the abstract stagnated or declined from 2009 to 2020. C_LIO_LIThe percentage of funded grants in which the abstracts focusing on female-specific health did not change across 2009-2020, but the percentage of funding dollars increased by 3.47%. C_LIO_LIThe percentage of grants in which the abstracts mentioned 2S/LGBTQ+-specific health more than tripled across 2009-2020 but remained less than 1% of all funded grants. C_LI

scientific communication and education↗